AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]
The age-related macular degeneration market across the seven major markets [...]
Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]
AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]
The age-related macular degeneration market across the seven major markets [...]
Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]